Medicaid Provider Spending

$1.09 trillion in Medicaid claims data, 2018–2024 · 617K+ providers

EMPIRE MEDICAL LLC

NPI: 1548629520 · CAMDEN, DE 19934 · Specialist · NPI assigned 02/18/2016

Billing Flags · Automated signals — not evidence of fraud
Entity Proliferation

Authorized official NGUYEN, HIEN controls 12+ related entities in our dataset. Read more

$6.93M
Total Medicaid Paid
235,666
Total Claims
108,525
Beneficiaries
25
Codes Billed
2018-01
First Month
2021-04
Last Month

Provider Details

Authorized OfficialNGUYEN, HIEN (MANAGING MEMBER)
NPI Enumeration Date02/18/2016

Related Entities

Other providers sharing the same authorized official: NGUYEN, HIEN

ProviderCityStateTotal Paid
RESPONSIVE HEALTH LLC CAMDEN DE $6.02M
HIEN AND DIANE NGUYEN DENTAL CORPORATION EL MONTE CA $956K
H & M DENTAL LLC HENDERSON NV $724K
DELAWARE WALK-IN MEDICAL, LLC CAMDEN DE $396K
RESPONSIVE MEDICAL LLC CAMDEN DE $286K
SMILE DESIGN DENTAL, P.A. PLANO TX $252K
EYE MAX INC GLOUCESTER VA $180K
NEW HEALTH OF NORTH EAST, LLC ELKTON MD $40K
LUU & NGUYEN DENTAL CORPORATION CHULA VISTA CA $24K
ABSOLUTE FAMILY DENTAL CARE, PA SAN ANTONIO TX $3K
EYEMAX, INC. GLOUCESTER VA $3K
HELOTES COSMETIC & FAMILY DENTISTRY, PLLC HELOTES TX $176.40

Monthly Spending Trend

Yearly Breakdown

YearClaimsTotal Paid
2018 81,276 $619K
2019 69,998 $1.94M
2020 65,117 $3.47M
2021 19,275 $898K

Billing Codes

CodeDescriptionClaimsBeneficiariesTotal Paid
80307 Drug test(s), presumptive, any number of drug classes; immunoassay 76,546 35,212 $2.05M
99214 Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity 24,166 10,843 $1.37M
99213 Office or other outpatient visit for the evaluation and management of an established patient, low complexity 37,248 17,031 $1.29M
G0481 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed 25,840 11,558 $1.23M
G0482 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed 31,326 14,427 $934K
99204 Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity 443 415 $40K
99203 Office or other outpatient visit for the evaluation and management of a new patient, low complexity 209 188 $6K
G0483 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed 2,616 1,418 $3K
99205 Prolong outpt/office vis 74 66 $3K
99211 Office or other outpatient visit for the evaluation and management of an established patient, minimal severity 130 120 $3K
99215 Prolong outpt/office vis 16 14 $2K
83992 2,535 1,144 $606.68
80299 2,376 1,121 $60.26
80362 2,501 1,135 $35.28
80348 2,535 1,144 $30.80
80365 2,533 1,145 $30.80
80346 2,535 1,144 $27.93
80358 2,536 1,145 $25.83
80324 2,535 1,144 $24.57
80353 2,536 1,145 $23.94
80367 2,536 1,145 $20.02
80359 2,552 1,145 $20.02
80345 2,535 1,144 $18.13
80335 2,535 1,144 $17.70
99072 4,272 2,388 $0.00